Emergent BioSolutions Wins $51.9 Million Contract for VIGIV

Emergent BioSolutions Gains $51.9 Million Contract Modification

Emergent BioSolutions Inc. has recently secured a contract modification worth $51.9 million to supply its product CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV). This award is part of the U.S. government's ongoing efforts to prepare for smallpox threats. This collaboration reinforces the company's role in public health safety.

Details of the Contract

The Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services, exercised an option from a 10-year contract initially signed in 2019 to procure additional doses of VIGIV. This treatment is crucial for addressing complications associated with smallpox vaccination.

Significance of the Award

According to Paul Williams, senior vice president at Emergent, securing this contract showcases the company’s strong partnership with the U.S. government. The aim is to fortify the nation's smallpox preparedness strategy. Williams emphasized their commitment to public health and readiness to supply life-saving solutions through their capabilities in North America.

About CNJ-016® (VIGIV)

CNJ-016® is an Immune Globulin (Human) solution indicated for treating complications resulting from the vaccinia vaccination. These complications include severe reactions such as eczema vaccinatum and generalized vaccinia. However, it is essential to note that VIGIV is not approved for post-vaccinia encephalitis treatment.

Health Alerts and Considerations

When administering VIGIV, specific precautions must be maintained. Notably, blood glucose testing in patients must be performed using a glucose-specific method to avoid misleading results caused by maltose content present in VIGIV. Monitoring for adverse reactions, such as hypersensitivity or acute renal dysfunction, is critical to ensuring patient safety.

Market Comparison and Impact

Emergent BioSolutions (NYSE: EBS) is positioned within a competitive market that emphasizes responsive healthcare solutions amid evolving global health threats. The necessity for robust biodefense measures, as evidenced by this contract, showcases the increasing importance of innovative medical countermeasures.

Community and Global Health Initiatives

With a mission to protect lives, Emergent BioSolutions has been pivotal in addressing public health emergencies. The company is committed to preparing communities globally against threats such as smallpox, botulism, and other health crises. Their ongoing efforts signify a proactive approach to ensuring health security.

Future Outlook

The recent contract modification reflects Emergent's alliance with governmental health agencies to bolster preparedness against potential biological threats. This contract may pave the way for further opportunities, reinforcing the critical supply chains necessary for effective public health responses.

Frequently Asked Questions

What is the purpose of the contract for VIGIV?

The contract is for providing Vaccinia Immune Globulin Intravenous (Human), a treatment for complications due to smallpox vaccination.

Who awarded Emergent this contract?

The U.S. Administration for Strategic Preparedness and Response (ASPR) awarded this contract modification.

What are the primary uses of VIGIV?

VIGIV is used primarily to treat complications from vaccinia vaccination, including severe cases like eczema vaccinatum.

What safety information is associated with VIGIV?

Patients must be monitored for reactions, particularly with blood glucose testing due to potential interference from maltose.

How is Emergent BioSolutions addressing public health threats?

Through innovative solutions and collaborations with governmental agencies, Emergent is dedicated to enhancing biodefense preparedness against health emergencies.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.